Volta Medical raises €2.3M in seed funding in a round led by Pasteur Mutualité Group.

Volta Medical, a Marseille, France-based med‐tech company that has developed an AI-based software tool used to guide cardiologists during heart surgeries, announced that it has raised €2.3 million ($2.6M) in seed funding.

The money was raised from investors led by the Pasteur Mutualité Group, which contributed with €2 million. The funding round came on the heels of the first tests performed with patients in Marseille (France) and following the hiring of Denis Hansjacob, a prominent figure in the med‐tech industry, as Chief Operating Officer.

The funds raised will be used to implement a European multicentric clinical trial in order to demonstrate the performance of Volta Medical’s AI software during heart surgeries; to expand the company’s R&D team for the development of new products; and to prepare the market launch of AIFib in 2020. AIFib is the first AI software in interventional cardiology capable of guiding surgeons during their procedures, specifically for the treatment of atrial fibrillation (AF).

Volta Medical was founded in 2016 in the south of France by 3 doctors and one engineer (Dr. Julien Seitz, Dr. Clément Bars (Marseille), Dr. Jérôme Kalifa and engineer Théophile Mohr Durdez), and develops artificial intelligence (AI) intended for interventional cardiology. The company's product, AIFib, is a SAAS developed to guide doctors through the complex medical procedure intended to treat atrial fibrillation, from the detection of electrical foci, which trigger atrial fibrillation, to the surgery itself.